BARCELONA — Researchers have reported encouraging early results from a clinical trial combining the experimental drug daraxonrasib with standard chemotherapy for patients with metastatic pancreatic cancer. The findings, presented on November 20 at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, showed substantial tumour responses in a group of patients whose disease had spread beyond the pancreas.

Microscopic image of human pancreatic tumour cells stained for laboratory research.
Microscopic image of pancreatic tumour cells. Dr. Lance Liotta Laboratory, US National Institutes of Health; public domain via Wikimedia Commons.

The phase I/II RMC-GI-102 study included 61 patients who received daraxonrasib alongside gemcitabine and nab-paclitaxel. According to the results presented at the symposium, 60.7 per cent of participants experienced an objective response, meaning their tumours shrank by a measurable amount or disappeared on assessment. Complete responses, in which tumours were no longer detectable using the study’s criteria, were recorded in 8.2 per cent of patients. The reported disease-control rate was 90.2 per cent. The European Organisation for Research and Treatment of Cancer published the trial findings.

Researchers also reported a median progression-free survival of 12.8 months, based on the available follow-up. Progression-free survival measures the time during which a patient’s cancer does not worsen or return, rather than how long a person lives overall. The median follow-up in the reported analysis was 18.3 months, and the data cut-off was September 28, 2026. These figures are encouraging but should not be interpreted as proof that the treatment cures pancreatic cancer.

Daraxonrasib is designed to target an active form of the RAS protein, a molecular switch involved in controlling cell growth. Changes in RAS signalling are common in pancreatic cancer and can help malignant cells continue multiplying. By interfering with this pathway, researchers hope to weaken a key mechanism that enables some tumours to grow and survive. The trial combined the experimental medicine with chemotherapy rather than testing it as a replacement for established treatment.

The most frequently reported adverse effects included rash, diarrhoea and fatigue, alongside side effects associated with chemotherapy, such as reduced blood-cell counts. The study report said treatment discontinuation because of daraxonrasib-related adverse effects was infrequent, occurring in five per cent of participants. Safety monitoring remains essential because early studies involve relatively small patient groups and may not reveal uncommon or longer-term complications.

Specialists have stressed that the results come from an early-phase study and that the trial did not compare the combination directly with a group receiving chemotherapy alone. That limitation makes it impossible to determine from these findings alone how much of the observed benefit is attributable to daraxonrasib. A larger randomised phase III study, RASolute-303, is intended to provide stronger evidence by comparing treatment approaches in a broader patient population.

Pancreatic cancer remains one of the most difficult cancers to treat, particularly when it has already spread to other organs by the time it is diagnosed. Treatment decisions depend on the cancer’s stage, the patient’s general health, tumour biology and available specialist care. The new results are therefore a research development, not a recommendation for patients to change or stop existing treatment. Anyone receiving cancer care should discuss clinical-trial options with their oncology team.

The next major question is whether the promising response rates will translate into longer survival and improved quality of life in a controlled phase III trial. Researchers will also need to establish which patients are most likely to benefit, how long responses last and how the treatment’s risks compare with existing options. Read more health reporting in the HeadlinesXtra Health section.

Source: EORTC-NCI-AACR Symposium, November 20, 2026. Photograph: Wikimedia Commons, Dr. Lance Liotta Laboratory / US National Institutes of Health, public domain.